본문으로 건너뛰기
← 뒤로

ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.

1/5 보강
Annales d'endocrinologie 2025 Vol.86(4) p. 101790
Retraction 확인
출처

Jannin A, Escande A, Hartl D, Louvel G, Breuskin I, Borson-Chazot F, Hadoux J, Lamartina L, Do Cao C, Deschamps F

📝 환자 설명용 한 줄

This article presents consensus recommendations by a multidisciplinary panel of endocrinologists, medical oncologists, pathologists, radiation oncologists, surgeons and nuclear medicine physicians.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Jannin A, Escande A, et al. (2025). ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.. Annales d'endocrinologie, 86(4), 101790. https://doi.org/10.1016/j.ando.2025.101790
MLA Jannin A, et al.. "ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.." Annales d'endocrinologie, vol. 86, no. 4, 2025, pp. 101790.
PMID 40379205

Abstract

This article presents consensus recommendations by a multidisciplinary panel of endocrinologists, medical oncologists, pathologists, radiation oncologists, surgeons and nuclear medicine physicians. The recommendations specifically address iodine-refractory well-differentiated thyroid carcinoma and locally advanced and/or metastatic medullary thyroid carcinoma. Treatment algorithms based on risk-benefit assessments of various multimodal therapeutic approaches are proposed for each clinical scenario. Given the limited data available on the management of these rare but aggressive forms of thyroid cancer, these consensus recommendations provide essential guidance for multidisciplinary teams to ensure optimal care for patients with these complex thyroid carcinomas.

MeSH Terms

Humans; Carcinoma, Neuroendocrine; Combined Modality Therapy; Iodine Radioisotopes; Neoplasm Metastasis; Thyroid Neoplasms

같은 제1저자의 인용 많은 논문 (2)